DE69222006T2 - Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten - Google Patents

Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten

Info

Publication number
DE69222006T2
DE69222006T2 DE69222006T DE69222006T DE69222006T2 DE 69222006 T2 DE69222006 T2 DE 69222006T2 DE 69222006 T DE69222006 T DE 69222006T DE 69222006 T DE69222006 T DE 69222006T DE 69222006 T2 DE69222006 T2 DE 69222006T2
Authority
DE
Germany
Prior art keywords
compositions containing
serotonin antagonists
containing histamine
multilayer compositions
multilayer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69222006T
Other languages
English (en)
Other versions
DE69222006D1 (de
Inventor
Yogendra Dandiker
Paul Derrick Huckle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919123026A external-priority patent/GB9123026D0/en
Priority claimed from GB919123044A external-priority patent/GB9123044D0/en
Priority claimed from GB929203364A external-priority patent/GB9203364D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE69222006D1 publication Critical patent/DE69222006D1/de
Publication of DE69222006T2 publication Critical patent/DE69222006T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69222006T 1991-10-30 1992-10-23 Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten Expired - Lifetime DE69222006T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919123026A GB9123026D0 (en) 1991-10-30 1991-10-30 Compositions
GB919123044A GB9123044D0 (en) 1991-10-30 1991-10-30 Compositions
GB929203364A GB9203364D0 (en) 1992-02-18 1992-02-18 Compositions

Publications (2)

Publication Number Publication Date
DE69222006D1 DE69222006D1 (de) 1997-10-09
DE69222006T2 true DE69222006T2 (de) 1998-01-22

Family

ID=27265908

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69222006T Expired - Lifetime DE69222006T2 (de) 1991-10-30 1992-10-23 Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten

Country Status (21)

Country Link
US (1) US5425950A (de)
EP (1) EP0546593B1 (de)
JP (1) JPH05194188A (de)
KR (1) KR930007439A (de)
AU (1) AU666880B2 (de)
BE (1) BE1005490A3 (de)
CA (1) CA2081709C (de)
CH (1) CH685536A5 (de)
CZ (1) CZ325792A3 (de)
DE (1) DE69222006T2 (de)
ES (1) ES2106818T3 (de)
FR (1) FR2683146B1 (de)
GB (1) GB2262445B (de)
IE (1) IE922775A1 (de)
IL (1) IL103593A0 (de)
IT (1) IT1263253B (de)
LU (1) LU88186A1 (de)
MX (1) MX9206236A (de)
NO (1) NO924183L (de)
NZ (1) NZ244921A (de)
TW (1) TW299236B (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5609884A (en) * 1992-08-31 1997-03-11 G. D. Searle & Co. Controlled release naproxen sodium plus naproxen combination tablet
GB9401894D0 (en) * 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
JPH07223970A (ja) * 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤
US6887461B1 (en) * 1998-10-26 2005-05-03 Genetics Institute, Llc Method of using IL-11 for treating mucositis
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
JPH0940561A (ja) * 1995-08-02 1997-02-10 Fujitsukusu Kk 瀉下剤
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
IN186245B (de) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
AU2004222771B2 (en) * 1998-07-30 2006-09-21 Pfizer Inc. Prevention of Migraine Recurrence
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
RU2236847C2 (ru) * 1998-11-02 2004-09-27 Илан Корпорейшн, Плк. Композиции в виде множества частиц с модифицированным высвобождением
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
US20080118556A1 (en) * 1998-11-02 2008-05-22 Elan Corporation, Plc Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
US6270807B1 (en) 1999-03-02 2001-08-07 L. Perrigo Company Taste-masked pharmaceutical composition
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
US20040258750A1 (en) * 1999-06-28 2004-12-23 Gerard Alaux Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
EP1064938A1 (de) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmazeutische Dosierungsformen zur kontrollierte Wirkstoffabgabe mit mindenstens ein pulsierendem Zeitverlauf
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
US6620431B1 (en) 2000-04-17 2003-09-16 Charles Signorino Shellac film coatings providing release at selected pH and method
IT1318571B1 (it) * 2000-06-09 2003-08-27 Farmaka Srl Composizioni cosmetiche per la cura del cuoio capelluto e dei capelli.
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
AU2002257582A1 (en) * 2001-02-14 2002-09-04 Glaxo Wellcome S.A. Pharmaceutical formulation
US20030072731A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing starch or dextrin
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
IL162459A0 (en) * 2001-12-24 2005-11-20 Teva Pharma Dosage form with a core table of active ingredientsheathed in a compressed annular body of powder o r granular material, and process and toolin
US20040013731A1 (en) * 2002-04-08 2004-01-22 Lavipharm Laboratories Inc. Drug-complex microparticles and methods of making/using same
US20060233875A1 (en) * 2002-07-19 2006-10-19 Mathur Rajeev S Taste masked sumatriptan tablets and processes for their preparation
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
SI1575566T1 (sl) * 2002-12-26 2012-08-31 Pozen Inc Veäśplastna dozirna oblika vsebujoäśa naproksen in triptane
EP1607092A4 (de) * 2003-03-17 2010-12-15 Takeda Pharmaceutical Zusammensetzungen mit kontrollierter freisetzung
US20040241252A1 (en) * 2003-05-29 2004-12-02 Abney Christopher Charles Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same
WO2004110492A2 (en) * 2003-06-06 2004-12-23 Glaxo Group Limited Composition comprising triptans and nsaids
US7390503B1 (en) * 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
JP2007507491A (ja) * 2003-09-29 2007-03-29 シージェー コーポレーション 徐放性製剤
GB0400452D0 (en) * 2004-01-09 2004-02-11 Norton Healthcare Ltd A pharmaceutical composition
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
CA2566384C (en) * 2004-05-28 2010-08-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US20060024361A1 (en) * 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
CN1993112A (zh) * 2004-07-29 2007-07-04 赛诺菲-安万特 用于具有高度pH依赖性溶解度的活性成分的控释的药物多层片剂
US20060024368A1 (en) * 2004-07-30 2006-02-02 Reza Fassihi Compressed composite delivery system for release-rate modulation of bioactives
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP1793808A1 (de) * 2004-09-29 2007-06-13 Aurobindo Pharma Limited Feste dosierungseinheitsformen von 5-ht1-agonisten
US20060240043A1 (en) * 2004-10-08 2006-10-26 Meyerson Laurence R Methods and compositions for treating migraine pain
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
BRPI0517166A (pt) * 2004-12-09 2008-09-30 Celgene Corp uso de d-treo-metilfenidato ou um sal do mesmo
EA200702221A1 (ru) * 2005-04-12 2008-04-28 Элан Фарма Интернэшнл Лимитед Композиции с контролируемым высвобождением для лечения бактериальной инфекции, содержащие цефалоспорин
WO2007037790A2 (en) * 2005-06-08 2007-04-05 Elan Corporation, Plc Modified release famciclovir compositions
EP3449928A1 (de) * 2005-11-28 2019-03-06 Imaginot Pty Ltd. Abgabesystem für eine orale therapeutische verbindung
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US9265732B2 (en) 2006-03-06 2016-02-23 Pozen Inc. Dosage forms for administering combinations of drugs
WO2007103113A2 (en) * 2006-03-06 2007-09-13 Pozen Inc. Dosage forms for administering combinations of drugs
EP2010162A4 (de) * 2006-04-03 2013-01-09 Isa Odidi Zusammensetzung zur abgabe eines arzneimittels
CN104825397A (zh) 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EA015304B1 (ru) 2006-08-03 2011-06-30 Нитек Фарма Аг Лечение ревматоидного заболевания глюкокортикоидами с отсроченным высвобождением
EP2124556B1 (de) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
KR100885029B1 (ko) * 2007-02-07 2009-02-23 지엘팜텍 주식회사 경구투여용 서방성 삼중정제
EP1970056A1 (de) * 2007-03-15 2008-09-17 Polichem S.A. Zeitspezifische Dosierformen mit verzögerter/pulsatiler Freisetzung
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
CA3066426A1 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
AU2009241847B2 (en) * 2008-04-28 2014-07-10 Zogenix, Inc. Novel formulations for treatment of migraine
WO2010084188A1 (en) * 2009-01-26 2010-07-29 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
NZ582836A (en) * 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
WO2010100657A2 (en) * 2009-03-04 2010-09-10 Fdc Limited A novel oral controlled release dosage forms for water soluble drugs
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
KR101572336B1 (ko) 2010-12-22 2015-11-26 퍼듀 퍼머 엘피 케이싱된 탬퍼 저항성 제어 방출 투여 형태
CN103327969A (zh) 2010-12-23 2013-09-25 普渡制药公司 抗篡改固体口服剂型
EA201500742A1 (ru) 2013-02-05 2015-12-30 Пердью Фарма Л.П. Защищенные от нецелевого использования фармацевтические композиции
WO2014133008A1 (ja) 2013-02-27 2014-09-04 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有するインドールおよびアザインドール誘導体
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
WO2015192122A1 (en) * 2014-06-13 2015-12-17 Avery Dennison Corporation Improved pressure-sensitive adhesives used for medical applications
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
DE3814532A1 (de) * 1988-04-29 1989-11-09 Bayer Ag Dhp-retard-zubereitung
US4880636A (en) * 1988-05-13 1989-11-14 Franz Robert M Film coated tablet of ranitidine HCl
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions

Also Published As

Publication number Publication date
EP0546593A1 (de) 1993-06-16
KR930007439A (ko) 1993-05-20
CZ325792A3 (en) 1993-10-13
AU2746992A (en) 1993-05-06
CA2081709A1 (en) 1993-05-01
AU666880B2 (en) 1996-02-29
NZ244921A (en) 1995-04-27
IL103593A0 (en) 1993-03-15
ITRM920788A1 (it) 1994-04-29
TW299236B (de) 1997-03-01
ITRM920788A0 (it) 1992-10-29
LU88186A1 (fr) 1993-05-17
IE922775A1 (en) 1993-05-05
FR2683146B1 (fr) 1995-05-12
MX9206236A (es) 1993-04-01
IT1263253B (it) 1996-08-05
ES2106818T3 (es) 1997-11-16
FR2683146A1 (fr) 1993-05-07
US5425950A (en) 1995-06-20
JPH05194188A (ja) 1993-08-03
GB2262445B (en) 1996-05-15
CA2081709C (en) 2003-09-02
NO924183L (no) 1993-05-03
GB9222662D0 (en) 1992-12-09
BE1005490A3 (fr) 1993-08-10
CH685536A5 (fr) 1995-08-15
GB2262445A (en) 1993-06-23
NO924183D0 (no) 1992-10-29
DE69222006D1 (de) 1997-10-09
EP0546593B1 (de) 1997-09-03

Similar Documents

Publication Publication Date Title
DE69222006D1 (de) Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten
DE69202186D1 (de) N-substituierte-4-Phenyl-Piperidin-Opioid Antagoniste.
DE69207351D1 (de) Fibrinogen-Rezeptor-Antagoniste
DE69232003T2 (de) Benzanilidderivate als 5-HT1D-Antagonisten
MX9204786A (es) Antagonistas del receptor 5-ht4 y composicion farmaceutica que los contiene.
DE69216347D1 (de) Polyolefinzusammensetzung
DE69207819D1 (de) Mehrschichtiger Behälter
FI924405A (fi) Lhrh-antagonister
PH31071A (en) Substituted pyrridopyrimidines useful antgiotensinII antagonists.
MX9100717A (es) Antagonistas de la bradiquinina
KR950703530A (ko) 5-HT4 길항제(5-HT4 Antagonists)
ITRM910952A0 (it) Composizioni farmaceutiche contenenti gonadotropine
DE69211675T2 (de) Ölzusammensetzungen
GB9217475D0 (en) Nauroprotective use cck antagonists
DE69209098T2 (de) Treppengeländer
DK0574510T3 (da) 2,4-Diaryl-1,3-dithiolaner som platelet activating faktor receptorblokkere og 5-lipoxygenasehæmmere
FI951798A (fi) Bentsofuraanijohdannaiset 5-HT1-kaltaisina reseptoriantagonisteina
DE69232141D1 (de) Sender-Empfänger
DE69225104D1 (de) PCT-Zusammensetzung
NO933170D0 (no) Heterocykliske forbindelser
DE69225266D1 (de) Bis-bibenzimidazol Zusammensetzung
BR9202742A (pt) Composicao delimpeza
NZ241872A (en) Substituted oxaspirononane paf antagonists
NO920398L (no) Flersjikts baererinnlegg
FI923151A (fi) Foerfarande foer framstaellning av vanadin-bis-arener fraon vanadinoxiklorid

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 546593

Country of ref document: EP